As of 6 Nov 2026, Mercury Laboratories trades at 21.6× trailing earnings, and the shares are 19% below their 52-week high. It earns ROCE of 10% and ROE of 5.6%, and sales grew 0.3% a year over 3 years while net profit fell 4.7%. Its dividend yield is 0.4%, and debt is 0.13× equity. It is a small-cap company with a market cap of ₹90 Cr; the shares fell 5.0% over the past year.
- ₹789.50
- ₹789.50
- ₹738.20
- ₹798.00
- 44
Health check
- ReturnsModest
−5.0% over the past year.
- Price tagNo peers
P/E 21.6, with no peers to compare.
- GrowthSlow
Sales +0.3%, profit −4.7% a year over 3 years.
- ProfitabilityAverage
ROCE 10.1%.
- Balance sheetSolid
Debt 0.13× equity, interest covered 53.3×.
- Red flags3 to check
Return on equity is low at 5.6%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹90 Cr
- Small cap
- P/E
- 21.6
- Price to book
- 1.53
- Book value ₹488.69
- Dividend yield
- 0.44%
- ROE
- 5.6%
- Return on equity
- ROCE
- 10.1%
- Return on capital employed
- Debt to equity
- 0.13
- Debt ₹7.89 Cr
- EPS (TTM)
- ₹34.69
- OPM (TTM)
- 10.7%
- Net margin 4.4%
- Sales growth
- −12.0%
- Latest quarter vs a year ago
- Profit growth
- −69.2%
- Latest quarter vs a year ago
- Price to sales
- 1.23
- EV/EBITDA 14.9
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 5.6%.
- Quarterly profit down 69.2% on a year ago.
- Quarterly sales down 12.0% on a year ago.
About Mercury Laboratories
Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system,…
- Headquarters
- Vadodara
- Employees
- 510
- Sector
- Healthcare
- ISIN
- INE947G01011
- Website
- mercurylabs.com
Price range
- Avg volume (3M)
- 56
- 1-year return
- minus 5.0%
- From 52-week high
- minus 19.2%
Peers
We couldn’t find listed peers for this company.
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 18.1 | 19 | 18.4 | 20.4 | 16 | |
| 15.8 | 16.9 | 15.8 | 18.4 | 14.8 | |
| 2.4 | 2.1 | 2.5 | 2 | 1.2 | |
| 13.0% | 11.2% | 13.7% | 10.0% | 7.5% | |
| 0.2 | 0.8 | 0.3 | 0.7 | 0.1 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.8 | 0.9 | 0.9 | 0.8 | 0.7 | |
| – | – | −0.4 | – | – | |
| 1.5 | 1.9 | 1.4 | 1.7 | 0.4 | |
| 37.5% | 14.5% | 30.2% | 29.4% | 24.0% | |
| 1 | 1.6 | 1 | 1.2 | 0.3 | |
| 8.06 | 13.69 | 8.31 | 10.21 | 2.48 |
Profit & loss
- Sales CAGR 3Y
- +0.3%
- Profit CAGR 3Y
- −4.7%
- EPS CAGR 3Y
- −4.7%
- ROE
- 5.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 75.3 | 75.6 | 75.1 | 75.9 | |
| – | +0.3% | minus 0.6% | +1.1% | |
| 66.3 | 65.1 | 67.3 | 66.9 | |
| 9.1 | 10.5 | 7.8 | 9 | |
| 12.1% | 13.9% | 10.3% | 11.9% | |
| 1.4 | 0.7 | 3.2 | 1.6 | |
| 0.1 | 0.1 | 0.2 | 0.2 | |
| 2.5 | 2.8 | 2.9 | 3.4 | |
| −0.5 | −1.4 | −3.2 | −0.4 | |
| 7.4 | 6.9 | 4.7 | 6.6 | |
| 25.1% | 18.3% | 32.5% | 27.2% | |
| 5.6 | 5.7 | 3.1 | 4.8 | |
| – | +1.4% | minus 44.4% | +53.7% | |
| 46.49 | 47.12 | 26.21 | 40.28 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.2 | 1.2 | 1.2 | 1.2 | |
| 44.4 | 49.6 | 52.4 | 56.9 | |
| 5.8 | 5.6 | 5.5 | 8.4 | |
| 12.7 | 11.6 | 15.2 | 12.6 | |
| 64.2 | 68 | 74.2 | 79.1 | |
| 24.4 | 27.8 | 34.8 | 34.1 | |
| 0.1 | 3.8 | 10.2 | 10.2 | |
| 0 | 0 | 0 | 0 | |
| 6.9 | 8.1 | 1.6 | 5.5 | |
| 32.8 | 28.2 | 27.7 | 29.2 | |
| 64.2 | 68 | 74.2 | 79.1 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 2.5 | 8.2 | 4.9 | 4.2 | |
| −1.1 | −6.3 | −9 | −3.2 | |
| −1 | −1 | −1.9 | 2.9 | |
| 0.4 | 0.9 | −6 | 4 | |
| −1.1 | −6.3 | −9 | −3.2 | |
| 1.4 | 2 | −4.2 | 1.1 | |
| −0.4 | −0.4 | −0.4 | −0.4 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.